Physicians typically evaluate body composition changes, any side effects, and metabolic markers before continuing or adjusting protocols
[2] [11] The American Diabetes Association recommends specific GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or indicators of high cardiovascular risk
Some individuals notice increased energy levels within a few days, while metabolism support may take a few weeks
Second, whether mTOR itself drives ferroptosis and governs Mller-cell function in DR has not been settled, and the molecular details of how the AMPK/mTOR axis steers their crosstalk are fragmentary
Ive personally been microdosing GLP-1s for over six months , and the results have been impressivenot just in body composition, but in behavioral alignment with healthy lifestyle goals , even in environments traditionally filled with temptation (like European vacations)